Current Report Filing (8-k)
May 16 2022 - 4:38PM
Edgar (US Regulatory)
0001614067
false
0001614067
2022-05-16
2022-05-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d) of the
Securities Exchange
Act of 1934
Date of Report (Date of earliest event reported)
May 16, 2022
Aridis
Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-38630 |
|
47-2641188 |
(State or other jurisdiction of
incorporation) |
|
(Commission File Number) |
|
(I. R. S. Employer
Identification No.) |
983 University Avenue, Bldg. B
Los Gatos, California 95032
(Address of principal executive offices, including
ZIP code)
(408) 385-1742
(Registrants telephone number, including
area code)
(Former name or former address, if changed since
last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class: |
|
Trading Symbol(s) |
|
Name of each exchange on which registered: |
Common Stock |
|
ARDS |
|
Nasdaq Capital Market |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 | Results of Operations and Financial Condition. |
On May 16, 2022, Aridis Pharmaceuticals, Inc.
issued a press release announcing financial and corporate results for the first quarter ended
March 31, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
The
information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any
registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
Item 9.01. | Financial Statements and Exhibits |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 16, 2022 |
ARIDIS PHARMACEUTICALS, INC. |
|
|
|
/s/ Vu Truong |
|
Vu Truong |
|
Chief Executive Officer |
Aridis Pharmaceuticals (NASDAQ:ARDS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aridis Pharmaceuticals (NASDAQ:ARDS)
Historical Stock Chart
From Apr 2023 to Apr 2024